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CObjectives: Single-size vials of drugs may be a source of waste and
increase in treatment costs. Bortezomib, indicated for multiple my-
eloma (MM) treatment, is available in 3.5-mg vials, a quantity higher
than the average dose commonly prescribed. This analysis aimed to
demonstrate, through real-world data, whichwould be the optimal vial
presentation for bortezomib in Brazil and quantify the reduction in
medication waste related to this option. Methods: From November
2007 to October 2009 all patients with MM treated with bortezomib
were identified via the Evidências database. Analysis of prescribed,
dispensed, and wasted doses, their costs and projections of the ideal
vial sizewere performed. Results: Thirty-five patients (mean body sur-
face area of 1.73 m2) received 509 infusions in 131 cycles of treatment
average of 3.77 cycles per patient). The average dose prescribedwas 2.1
g per infusion (95% confidence interval [CI] 1.97–2.26) with average O
e no
eri, 1
al So
oi:10.1016/j.jval.2011.05.013aste of 39.5% of the vial content (95% CI 35.35–43.76). Themeanwaste
er patient per day was 1.38 mg (95% CI 1.24–1.52). If a 3-mg vial were
vailable, the average drug waste per patient per day would be 0.88 mg
95% CI 0.74–1.03) or 36.2% less. With a 2.5-mg vial the waste would be
.05mg (95%CI 0.81–1.29) or 23.9% less. If two presentationswere avail-
ble (2.5 mg and 0.5 mg), the waste would be 0.52 mg (95% CI 0.4–0.63)
r 62.5% less. Considering the price of the different vials to be propor-
ional to the original 3.5-mg vial, the cost would be also reduced by the
ame rates described above. Conclusions: A simple adjustment in vial
ize may reduce the waste of bortezomib by 36% to 62% and can also
educe the cost of treatment.
eywords: bortezomib, cost-reduction, drug waste, myeloma.
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Multiple myeloma (MM) is considered a chronic disease for which—
despite many advances in therapy—there is currently no curative
treatment available. Thedevelopment of novel agents that target the
tumor cell and the microenvironment, immunomodulators, protea-
some inhibitors, and bisphosphonates has changed the standards of
care for affected patients. Even with the achievement of complete
responses in few cases, the ultimate goals for patients with MM are
extended survival and quality of life [1–4].
Thecostsassociatedwithcurrentandemerging therapies, aswell
as supportive care, are significant and pose a tremendous financial
burden to both patients and health care systems [5]. This is an im-
portant aspect to be considered, especially in underdeveloped coun-
tries and emerging economies in which the bulk of resources des-
tined to health care is often reduced and unevenly distributed.
Newer classes of cytotoxic agents are, for the most part, very
expensive and there may be considerable resource savings in the
judicious application of dose rounding without any negative clin-
ical effect, given the significant interpatient pharmacokinetics
and pharmacodynamics variability for most cytotoxic drugs [6].
Single-size vials of chemotherapy drugs may be an undernoticed
source of waste and increase in treatment costs. There is, how-
ever, the possibility of customizing the dose of chemotherapy for
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ublished by Elsevier Inc.each patient not only by the body surface area (BSA) measure-
ment, but also by adjusting the final dose to the nearest vial size.
Previous published studies described this kind of adjustment as
cost saving in several types of chemotherapy treatments [6,7].
Bortezomib (Velcade, Janssen-Cilag, Beerse, Antwerp, Belgium) is
adrug frequentlyused inMMtreatment that is available inBrazil and
inmanyother countries only as a 3.5-mgvial. This presentationdose
is higher than the average dose commonly prescribed and due to the
lack of preservatives in the vial, it is mandatory that the drug be
administered within 8 hours of preparation. This analysis aimed to
demonstrate, through real-world data, which would be the optimal
vial presentation for bortezomib in Brazil and to quantify the reduc-
tion in medication waste and costs related to it.
Study design
This study is a retrospective analysis of data extracted from Evi-
dências Database (ED), an electronic system design to evaluate
chemotherapy requests fromhealth care providers and permit the
approval or denial of coverage by auditors. The database is avail-
able as a secure Web site where patient data such as age, disease
stage, BSA, and drugs requested among other information are pro-
spectively stored. ED covers approximately 5% of the Brazilian pri-
conflicts of interest with regard to the content of this article.
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perspective on the private health care system.
During the period of November 2007 to October 2009, all pa-
tients diagnosedwithMM (cases entered into EDwith the Interna-
tional Statistical Classification of Diseases and Related Health
Problems code C90.0), submitted to treatment containing bort-
ezomib for at least one infusion were identified. All patients were
treated in private care referral cancer centers, according to usual
chemotherapy protocols and identified on the auditing medical
system.
Details regarding the prescribed dose of bortezomib, individu-
ally and collectively wasted doses, and the respective average
doses per patient and per cycle were retrieved. The actual dose
dispensed to perform the infusion was also calculated. That is
important because it is often necessary to open multiple vials to
fulfill the prescribed dose, thus accounting for increased waste.
The costs of the wasted drug and the projection of costs saved
with different vial sizes were calculated.
The mean and average calculations were performed based on
usual mathematical formulas and were represented as milli-
grams, US dollars, the Brazilian currency reals (R$), or square me-
ters, according to the variable studied. The results are reported
with the corresponding 95% confidence interval (CI). The amount
of drug wasted was also expressed in percentage related to the
total content of the 3.5-mg vial. The results of costs were ex-
pressed in US dollars with the cost of the 3.5-mg bortezomib vial
being R$4218.33 or US$2343.51 (exchange rate R$1.80 to US$1 as of
May 2010). The price list used was the Brazilian Official Price List
[8], determined by the federal government, by the wholesale price
plus taxes. Differently sized vials were priced proportionally to the
existing vial for economic projections.
No patient was identified by name or any particular character-
istic during this study. All health care providers previously autho-
rized the data extraction in signed contracts. Because the purpose
of this study was to evaluate the optimal presentation for bort-
ezomib, the clinical aspects and the outcomes regarding effective-
ness and security of this drug were not taken into consideration.
Results
Thirty-five patients with MM treated with bortezomib (alone or in
association with other cytotoxic drugs) were identified on ED. The
mean body surface area was 1.73 m2. The average prescribed dose
per infusion was 2.1 mg (95% CI 1.97–2.26) with average waste of
39.5% of the vial content (95% CI 35.35–43.76) of the contents of a
standard 3.5-mg vial per day or 5.39 mg per cycle. The patients
received a total of 509 days of infusion distributed in 131 cycles of
treatment (average of 3.77 cycles per patient).
During the period of time analyzed, a total of 1781.5 mg were
dispensed to cover 1075.7 mg prescribed, resulting in a gross loss
of 705.7 mg (39.6%) of bortezomib. That means that of the
US$1,192,841.50 spent on the drug, US$472,365.23waswasted. The
total amount of resource wasted per day, with all 35 patients, was
US$121,420.95. Those data are described in Tables 1 and 2 in the
Supplemental Materials found at: doi:10.1016/j.jval.2011.05.013.
The averagewaste projections for every patient per day andper
cycle of treatment, respectively, according with the different vial
sizes proposed is described in Table 2 (in Supplemental Materials
found at: doi:10.1016/j.jval.2011.05.013). The percentage is defined
in regard to the standard 3.5-mg vial. For a 3-mg vial, 0.88 mg/day
(95% CI 0.74–1.03) or 36.2% less and 3.44 per cycle (95% CI 2.85–
4.04). For a 2.5-mg vial, 1.05mg/day (95% CI 0.81–1.29) or 23.9% less
and 4.06 mg per cycle (24.6% more than with the 3.5-mg vial).
If two different presentations were available, 2.5 mg and 0.5
mg, the waste per patient per day would be 0.52 mg (95% CI 0.4–
0.63) or 62.5% less and 2.01 mg/per cycle (62.7% less than with
3.5-mg vial).The cost reduction projections per day and per cycle, respec-
tively, assuming a proportional price of the proposed vials to the
3.5-mg vial, are described in Table 3 in the Supplemental Materials
found at: doi:10.1016/j.jval.2011.05.013.
Using the currently available 3.5-mg vial, an average of
US$926.88/day and US$3,607.33/cycle are lost. If a 3-mg vial were
available, the average loss would be US$592.09/day (36.1% less
than with the 3.5-mg vial size) and US$2306.51/cycle.
With the 2.5-mg vial, the averagewaste per patient per daywas
US$704.54 (23.9% less than with the 3.5 mg vial size but 15.9%
higher than with the 3-mg vial size) and $2717.97 per cycle.
If considering the combination of 2.5-mg plus 0.5-mg vials
sizes, the loss would be US$346.75/day (62.5% less than with the
3.5-mg vial size) and US$1348.15 per cycle (62.6% less). The total
costwasted per day for all 35 patientswasUS$45,424.01 (62.5% less
than with the 3.5-mg vial size) or US$176,607.25 per cycle.
Discussion
Although MM accounts for only a small percentage of all can-
cers, the costs associated with treating and managing it are
among the highest [9]. Recent developments in diagnosing,
treating, and managing MM have led to novel treatment strate-
gies. Immunomodulators, proteasome inhibitors, and bisphos-
phonates are improving response rates and preserving patients’
quality of life [10]; however, these agents are not replacing the
older treatment modalities, but rather being used in addition to
them [11].
The landscape of myeloma therapy has changed radically
since 1999 with the introduction of new therapies and better prog-
nostic indicators ushering in a new era of MM management [10].
Novel agents resulting in extended survival and better under-
standing of the biology of the disease have helped select patients
most likely to benefit from stem cell transplantation. The costs
associated with current and emerging therapies, as well as sup-
portive care are significant and likely to increase further on, as
patients begin to live longer [5].
Furthermore, the majority of cytotoxic chemotherapy proto-
cols are based on dosage calculation from BSA. There is a growing
body of evidence that demonstrates the large interpatient variabil-
ity associatedwith dosing by BSA [12–16]. Despite this known vari-
ability, it is common practice for clinicians to calculate doses of
chemotherapy to the nearestmilligram based on BSA estimated to
two decimal points [12]. In some instances dose rounding is em-
ployed by the clinician (e.g., capping) and in others by pharmacists
preparing the drug, but this is still more the exception than the
rule [12]. There are practical implications related with costs and
unnecessary losses in preparing cytotoxic doses calculated to the
exact milligram.
Mertens et al. [11] conducted a study aimed to evaluate the
effects of dose rounding on treatment cost. During the study pe-
riod, 18 different anticancer drugs were administered 939 times. If
dosagehad been based strictly onBSA, drug costswouldhave been
€509,664. Rounding off to whole ampoules with a dose margin of a
maximum of 10% would have cost €465,619; a reduction of 8.6%.
The rational application of the dose individualization principle
based on body surface areamay result in a substantial reduction in
expenditure on anticancer drugs [11].
Dose rounding has been considered acceptable to within 5% of
calculated dose because on the basis of pharmacokinetic and clin-
ical issues this dose adjustment is not expected to have any sig-
nificant effect on either response or toxicity [6,17–19].
Another possibility to help solve thewaste problemwould be to
combine multiple infusions on the same day. In terms of our
study, however, it would be highly unlikely, not only because of
the rarity of the disease but also due to the fact that the 35 patients
were located in 10 different states in Brazil.
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bortezomib vials was because usually drug prices in Brazil are
calculated to be proportional to their dosage; that is, if a medica-
tion is available in 50- and 100-mg vials, the latter will be twice as
expensive as the former [8].
Drug waste may be defined as the consequence of an inappro-
priate disposal of unused or partially used ampoules, vials, or sy-
ringes of drugs [20]. It has been previously demonstrated that in-
efficiency of drug use and waste production may lead to a distinct
economic loss, though experiences are limited and most studies
are dated or focus on other therapeutic areas [9,20–22]. Decreasing
waste is an attractive cost-cutting strategy because it neither lim-
its specific drug use nor affects quality of care [7].
One of the main reasons for drug waste was essentially the lim-
ited extent of chemotherapy medication shelf-life and the narrow
availability of a range of vial sizes flexibly matching with possible
drug dosages [7]. Adopted corrective measures were the logical con-
equenceof thesefindings: if drug instability is abasis fordrugwaste,
t is reasonable to use,whenever possible,multidose vials that retain
much longer microbial and chemical stability and to operate a per
athology/per drug distribution system of chemotherapy sessions
ver the week to allow the reuse of leftovers in other patients while
especting drug stability [7].
One of the limitations of this study was its small sample size.
Although we used a database that covers 5% of the Brazilian pri-
vate health care market, MM is much less frequent than other
neoplasms such as breast or colon cancer and therefore it are
important that these findings are confirmed in larger cohorts of
patients.
Finally, there has been much discussion on the rising prices of
oncologic treatments and how much is too much [23]. We believe
that this discussion is even more important in developing coun-
tries, which are plagued by a perennially insufficient health care
budget. To keep the discussion active we made this analysis and
intended to show how the simple adjustment of vial size in bort-
ezomib could affect costs and minimize drug waste.
Conclusions
A simple adjustment in vial size from 3.5 to 3.0 mg reduces bort-
ezomib waste by 36%. If presentations of 2.5 mg and 0.5 mg were
available, the waste reduction could be as high as 62%.
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